Education
About Us
Working with TipRanks
Follow Us
Immuron Limited (DE:ANW)
FRANKFURT:ANW
ANW Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EST
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.66M
Enterprise Value€5.02M
Total Cash (Recent Filing)€5.87M
Total Debt (Recent Filing)€117.13K
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Mar 04, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding326,653,600
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.75
Price to Sales (P/S)1.93
P/FCF Ratio-2.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial Product Plus Clinical PipelineOwning a marketed oral product (Travelan) gives an ongoing commercial revenue stream and distribution relationships, while IMM-124E and other pipeline assets provide durable upside via regulatory approval, licensing or partnership opportunities that can diversify revenue beyond one product.
Conservative LeverageExtremely low financial leverage reduces bankruptcy and interest-rate risk and preserves flexibility to raise funds for clinical programs or commercialization. For a biotech with long development timelines this structural balance-sheet strength supports resilience through multi-quarter cash burn periods.
Positive Revenue GrowthConsistent year-over-year revenue growth indicates strengthening commercial traction for existing offerings. Sustained top-line growth creates a base to improve operating leverage over time, supporting margin recovery if fixed costs are spread across higher volumes or if sales channels scale.
Bears Say
Ongoing Unprofitable OperationsPersistent negative profitability means the business is not yet self-sustaining and must rely on external funding or dilution. Over months to years this limits reinvestment in R&D and commercialization, raises financing risk and pressures management to achieve structural margin improvements.
Negative Operating And Free Cash FlowNegative operating and free cash flow reduce financial flexibility and shorten runway for trials and market expansion. For a small biotech, sustained cash burn forces frequent capital raises or partnering, which can delay programs, increase dilution, or constrain long-term strategic options.
Weak Returns On CapitalA negative ROE signals the company is not generating adequate returns from capital employed, reflecting structural inefficiency. Over time this undermines investor confidence, complicates capital raising and may necessitate strategic changes or reliance on partners to improve capital productivity.
Immuron Limited News
ANW FAQ
What was Immuron Limited’s price range in the past 12 months?
Immuron Limited lowest stock price was €0.01 and its highest was €0.05 in the past 12 months.
What is Immuron Limited’s market cap?
Immuron Limited’s market cap is €5.66M.
When is Immuron Limited’s upcoming earnings report date?
Immuron Limited’s upcoming earnings report date is Mar 04, 2026 which is in 12 days.
How were Immuron Limited’s earnings last quarter?
Immuron Limited released its earnings results on Sep 02, 2025. The company reported €0 earnings per share for the quarter, the consensus estimate of N/A by €0.
Is Immuron Limited overvalued?
According to Wall Street analysts Immuron Limited’s price is currently Overvalued.
Does Immuron Limited pay dividends?
Immuron Limited does not currently pay dividends.
What is Immuron Limited’s EPS estimate?
Immuron Limited’s EPS estimate is 0.
How many shares outstanding does Immuron Limited have?
Immuron Limited has 326,653,600 shares outstanding.
What happened to Immuron Limited’s price movement after its last earnings report?
Immuron Limited reported an EPS of €0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Immuron Limited?
Currently, no hedge funds are holding shares in DE:ANW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immuron Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.31%
12-Months-Change
Fundamentals
Return on Equity
-49.96%
Trailing 12-Months
Asset Growth
-41.64%
Trailing 12-Months
Company Description
Immuron Limited
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III registration trial to reduce the risk of contracting travelers' diarrhea in the United States, and Phase II field trial for Travelers' Diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in Phase I/IIa clinical trial for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
Technical Analysis
Noxopharm Ltd.
―
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Anatara Lifesciences Ltd
―
Neuroscientific Biopharmaceuticals Ltd.
―